Evotec Results Presentation Deck

evotec "Evotec Inside" Fully invested pipeline gaining visibility Progress of drug candidates in advanced stages Selected pipeline events within next 18 - 24 months • Phase III data (China) with JingXin in insomnia • Phase Ilb data with Bayer in RCC (eliapixant) • Phase II data with Bayer in Overactive bladder (eliapixant) • Phase II with Bayer in Endometriosis (eliapixant) • Phase II with Bayer in Neuropathic pain (eliapixant) Phase II with Bayer in Gynaecology (B1 antagonist) • Phase I data in Chikungunya virus Phase I initiation with BMS in CNS • Phase I data with Exscientia in Oncology (A2a) • Phase I initiation with Kazia in Oncology (EVT801) Phase I with Sanofi in HBV PAGE 24 Multiple co-owned equity companies will progress in clinic (e.g. Topas, Forge, Carrick, Fibrocor, ...) Clinical Pre-clinical Discovery Molecule EVT201 BAY-1817080 Therapeutic Area/Indication Insomnia (GABA-A) Chronic cough (P2X3) BAY-1817080 Overactive bladder BAY-1817080 Neuropathic pain BAY-1817080 Endometriosis CT7001 CT7001 EVT401 BAYXXX BAY2328065 BI 894416 BI 860585 TPM203 DSP-1181 CNTX 6016 EVT894 BAYXXX EVT801 APN411 EXS21546 GLPGXXXX BAYXXXX QRB001 BMSXXXX EVT895 EVTXXXX Oncology (CDK7) Oncology (CDK7) Immunology & Inflammation (P2X7) Women's health Gynaecology Asthma (not disclosed) Oncology (mTORC1/2) Pemphigus Vulgaris (not disclosed) Obessive-compulsive disorder (5-HT1A) Pain (CB2) Chikungunya (Antibody) Endometriosis (not disclosed) Oncology (VEGFR3) Oncology - Immunotherapy Oncology (various programmes) Fibrosis (not disclosed) Nephrology (not disclosed) Metabolic Diabetes (not disclosed) Neurodegeneration (not disclosed) HBV CNS, Metabolic, Pain ... Partner 入京新药业 INGAN PHARMACEUTICAL Carrick 12 occutics Carrick 12occutics 克斯坦奥集团 CONEA GROUP BAYER Boehringer Ingelheim Boehringer Ingelheim Topas Therapeutics Exscientia Boehringer Ingelheim NIH SANOFI SANOFI SIOLOGICS SANOFI APEIRON Exscientia Galápagos QRbeta THE RAFELTICS Bristol Myers Squibb SANOFI >10 further programmes Discovery Pre-clinical Phase I Phase II Multiple programs across nephrology, oncology, immunology among other therapeutic areas Phase III

View entire presentation